All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas a retrospective study of 132 patients

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375389" target="_blank" >RIV/00216208:11130/18:10375389 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064211:_____/18:W0000140

  • Result on the web

    <a href="https://doi.org/10.1080/09546634.2017.1329507" target="_blank" >https://doi.org/10.1080/09546634.2017.1329507</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1080/09546634.2017.1329507" target="_blank" >10.1080/09546634.2017.1329507</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas a retrospective study of 132 patients

  • Original language description

    Objective: To evaluate effectivity, safety and patients&apos; adherence to benzathine penicillin G (BPG) 1,200,000 units (1.2MU) once-every-3-week intramuscularly prophylaxis for recurrent erysipelas.Methods: Patients with documented two or more erysipelas episodes in last two years who received at least one of 10 planned doses of BPG 1.2MU intramuscularly between January 2009 and December 2015 were analyzed in this retrospective study. Number of recurrences during the 30-week prophylaxis and in the 30-week follow-up period, frequency of adverse events, patients&apos; adherence to the treatment and factors associated with the recurrence were analyzed.Results: From 132 patients, 109 (82.6%) finished the 30-week prophylactic regimen successfully. The incidence of erysipelas was 8 per 100 patient-years during the prophylactic period and 28 per 100 patient-years in the follow-up period (incidence rate ratio=0.20; 95% CI: 0.05-0.34; p&lt;.01). In univariate analysis recurrence was significantly associated only with presence of any local risk factor concurrently with obesity (OR 3.40; 95% CI: 1.10-10.50; p&lt;.05).Conclusion: Benzathine penicillin G 1.2MU once every 3weeks is an effective and well-tolerated prophylaxis of recurrent erysipelas with good patient adherence to the treatment. Further studies to determine the appropriate duration of prophylaxis are necessary.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30216 - Dermatology and venereal diseases

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Dermatological Treatment

  • ISSN

    0954-6634

  • e-ISSN

  • Volume of the periodical

    29

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    5

  • Pages from-to

    39-43

  • UT code for WoS article

    000423855400009

  • EID of the result in the Scopus database

    2-s2.0-85019681675